Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in the field of liver diseases, announced today a non-exclusive collaboration with GAT Therapeutics, an early stage biopharma targeting fibrosis and age-related diseases.

Under the terms of the agreement, BLB will deeply characterize the effects of GATTx’s lead compound GTX-011 on non-alcoholic steatohepatitis (NASH), liver cirrhosis and portal hypertension. The research plan incorporates different BLB’s proprietary methods & technology, including the BarNa model®, unique pre-clinical model of NASH that mimics key pathophysiological and transcriptomic features of the human disease, and the exclusive ExoLiver® platform, BLB’s advanced model of human liver disease.

BLB aims at providing valuable insights into complex disease pathways and drug responses in a more meaningful liver disease pre-clinical context. For more information please visit www.liver.barcelona

Barcelona Liver Bioservices (BLB) announced today the presentation of two communications at the annual meeting of the American Association for the Study of the Liver (AASLD), held in Boston, Massachusetts.

Oral communication #0063 “The pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease” will be presented by Dr Jordi Gracia-Sancho, CEO & CSO of BLB, on Sunday November 10th at 11:00h at the Hynes Auditorium. The study, fruit of the collaboration between BLB and Inventiva, describes for the first time the effects of the pan-PPAR agonist lanifibranor in a pre-clinical model of advanced cirrhosis. Results of the study show that rats receiving lanifibranor exhibited significant improvement in portal hypertension, which was associated with reduction in intrahepatic vascular resistance. Underlying mechanisms of this hemodynamic improvement included amelioration of hepatic stellate cells (which displayed normalization of several cell activation markers) and liver sinusoidal cells (showing improvement in capillarization markers and increment in fenestrae porosity). Importantly, lanifibranor administration led to partial regression of liver fibrosis. “We are glad to describe in detail the benefits of this compound in a pre-clinical model of advanced chronic liver disease, which supports further inhouse research using ExoLiver®: BLB’s proprietary drug-discovery platform that mimics the human sinusoid in vitro”, stated Dr Gracia-Sancho.

Poster #2116 “Hepatic fatty acid profile in chronic liver disease: mechanism of injury and novel therapeutic target” will be displayed on Monday 11th from 8:00 – 17:30h and presented by Zoe Boyer, Senior Associate Scientist at BLB. The study characterized the hepatic fatty acid de-regulation that may occur in advanced chronic liver disease, and investigated the possible therapeutic benefit of administering a nutraceutical rich in docosahexaenoic acid triglycerides (DHA) as a possible approach to re-establish a healthy lipid profile. The results of this project, which was performed in collaboration with BrudyLab, revealed that rats with cirrhosis exhibited a profoundly deregulated liver fatty acid profile, both structurally and enzymatically, indicating that chronic liver injury increases de novo lipogenesis in the liver and alters fatty acid metabolism, pathways that are recognized as important contributors to the development of metabolic disorders. Interestingly, when treated with BrudyLab-DHA, cirrhotic animals presented a remarkable improvement in their hepatic fatty acid composition, reaching values comparable to those of healthy animals.

Barcelona Liver Bioservices Team will be in Boston during the entire AASLD meeting. Please contact us to set up a private meeting to discuss how BLB can assist you to foster the development of new therapeutics for liver disease, including NASH and cirrhosis.

Barcelona Liver Bioservices announced today the publication of the manuscript entitled “A nutraceutical rich in docosahexaenoic acid improves portal hypertension in a preclinical model of advanced chronic liver disease” in the peer-reviewed journal Nutrients.

Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “A nutraceutical rich in docosahexaenoic acid improves portal hypertension in a preclinical model of advanced chronic liver disease” in the peer-reviewed journal Nutrients. The study describes the pre-clinical research developed in collaboration with BrudyLab, biotech company specialized in the development and commercialization of molecules derived from omega-3 fatty acid.

“The study demonstrates the beneficial effects of BrudyLab’s unique DHA formulation improving the hepatic fatty acid profile, portal pressure, inflammation and hepatic stellate cells phenotype in pre-clinical models of advanced chronic liver disease” summarizes Zoe Boyer, Associate Scientist at BLB and first author of the manuscript.

According to BLB & BrudyLab partnership, both entities will continue working together to further understand the underlying mechanisms of Brudy’s patent-protected compound while exploring possibilities to offer it to patients with chronic liver disease. “We very much look forward to continuing working with BrudyLab, due to its antioxidant properties their DHA formulation has high potential as nutraceutical supplement for liver diseases. Particularly, its benefits on fatty acid profile, inflammation and portal hypertension suggest high applicability for the treatment of NASH” stated Dr Jaime Bosch, vice-president of clinical research at BLB.

View full article

For more information about the company, current partners and available research services please visit www.liver.barcelona

Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease” in the peer-reviewed journal Cells. The manuscript describes BLB’s proprietary model of non-alcoholic steatohepatitis, termed BarNa Model®.

“It is recognized that NASH-derived cirrhosis is a burden of disease in our Society, with no therapeutic option available. Considering that no pre-clinical model properly mimics the human pathobiology of the disease, we at BLB invested significant efforts to develop a novel model of advanced NASH in rats that fulfil major clinical characteristics (including steatosis, inflammation, advanced fibrosis and portal hypertension) and shares a significant part of molecular pathways involved in the human disease” affirmed Dr Jordi Gracia-Sancho, CEO & CSO of BLB.

This new and unique model of advanced NASH can be used to test new drug entities designed to treat NAFLD and NASH, and to understand their underlying mechanisms of action, in a complex biological system with marked similarities with the human disease.

BarNa® animals are now available to current and future BLB’s partners, just get in touch with us to start a new research endeavor in the field of metabolic liver diseases.

View full article

Barcelona Liver Bioservices is a CRO focused on the design and development of pre-clinical research in the field of Hepatology. The company offers cutting-edge research services and consulting to foster the development of new therapeutics for liver diseases, including non-alcoholic steatohepatitis and cirrhosis.

For more information about the company, current partners and available research services please visit www.liver.barcelona

The study characterizes the effects, and underlying mechanisms, of the pan-caspase inhibitor emricasan on portal hypertension, fibrosis and liver cells phenotype in pre-clinical models of advanced cirrhosis. It integrates a variety of BLB’s experimental approaches, including the unique ExoLiver® platform, animal models of cirrhosis, and cellular secretome analysis, among others.

View full article

Barcelona Liver Bioservices is a CRO focused on the design and development of pre-clinical research in the field of Hepatology. The company offers cutting-edge research services and consulting to foster the development of new therapeutics for liver diseases, including non-alcoholic steatohepatitis and cirrhosis.

For more information about the company, current partners and available research services please visit www.liver.barcelona

Barcelona Liver Bioservices (BLB) announced today the presentation of two posters at the annual meeting of the European Association for the Study of the Liver (EASL), held in Vienna.

Poster #FRI 110 “A nutraceutical supplement rich in docosahexaenoic acid improves portal hypertension in a pre-clinical model of chronic liver disease” will be displayed today from 09:00 – 17:00h and presented by Zoe Boyer, Associate Scientist at BLB. The study, developed within the partnership of BLB with BrudyLab, investigates the effects of an antioxidant nutraceutical supplement rich in docosahexaenoic acid triglycerides (DHA-TG) in pre-clinical models of chronic liver disease and portal hypertension. Results of the study demonstrate that 2-week DHA-TG promoted a significant amelioration in portal hypertension, without changes in portal blood flow, thus suggesting improvement in intrahepatic vascular resistance. The mechanisms underlying this hemodynamic improvement included significant reductions in hepatic oxidative stress, de-activation of hepatic stellate cells, and reduction in liver fibrosis. “It is remarkable that the effects of this natural compound were similar to other small molecules specifically designed to treat human liver diseases, thus representing an ideal compound to be combined with other drug entities” affirmed Prof Jaime Bosch, co-founder and scientific advisor of BLB.

Poster #FRI 324 “Introducing a new pre-clinical model of advanced NASH that mimics the main pathophysiological characteristics and transcriptomic signature of the human disease” will be displayed today from 09:00 – 17:00h and presented as selected oral Poster tomorrow at 13:00h. The work introduces the unique BLB’s pre-clinical model of NASH, termed Barcelona Nash – BarNa Model®. The experimental model, which is based on a multi-hit protocol that combines pro-inflammatory and pro-steatosis injuries, mimics the major clinical descriptors of the human disease: steatosis & metabolic syndrome, lipotoxicity, hepatic inflammation, hepatic stellate cells activation and stablished fibrosis, and portal hypertension. Analysis of the liver transcriptome using NGS demonstrated that the BarNa model shares de-regulations in a significant part of the pathways involved in the human disease pathophysiology, including insulin resistance, lipid metabolism, cell death, inflammation, fibrosis, endothelial dysfunction and mitochondrial dysfunction. The BarNa model®, which is now available for new partnerships, is developed in rats allowing proper analysis of hemodynamic parameters and isolation of high number of primary cells.

Barcelona Liver Bioservices is a CRO focused on the design and development of pre-clinical research in the field of Hepatology. The company offers cutting-edge research services and consulting to foster the development of new therapeutics for liver diseases, including non-alcoholic steatohepatitis and cirrhosis.

For more information about the company, current partners and available research services please visit www.liver.barcelona

Barcelona Liver Bioservices (BLB), CRO especially focused on the field of Hepatology, announced today its participation in the upcoming International Liver Congress (ILC) 2019 – the annual meeting of the European Association for the Study of the Liver (EASL) that will take place in Vienna in April 10-14th 2019.

BLB’s participation in the meeting will include scientific contribution and official representation. From the scientific point-of-view, BLB will present the results of two studies: The works entitled “A nutraceutical supplement rich in docosahexaenoic acid improves portal hypertension in a pre-clinical model of chronic liver disease” and “Introducing a new pre-clinical model of advanced NASH that mimics the main pathophysiological characteristics and transcriptomic signature of the human disease” will be presented by Zoe Boyer-Díaz, Associate Scientist at BLB, and Dr Jordi Gracia-Sancho, CEO and CSO of the company.

In addition to science, BLB is glad to announce its further contribution with the ILC-2019 being part of the Biotech Village. BLB’s working and management teams will be available to meet in the unique BLB’s stand. Look for us to talk about liver research, while having a cup of coffee, in the Biotech Village, stand no. 1!

For more information about the company, current partners and available research services please visit www.liver.barcelona

Barcelona Liver Bioservices (BLB) announced today the presentation of a poster describing the mechanisms of action of emricasan in liver cirrhosis at the 69th annual meeting of the American Association for the Study of the Liver (AASLD), held in San Fransico, CA.

Poster #1344 “Molecular Mechanisms Underlying the Beneficial Effects of Emricasan in Portal Hypertension and Chronic Liver Disease: Relevance of the Hepato-Sinusoidal Cross-Talk” will be displayed from 14:00 – 19:30h and presented by Zoe Boyer, Associate Scientist at BLB. The study investigates the underlying mechanisms of emricasan improving portal hypertension and fibrosis in pre-clinical models of advanced chronic liver disease. Characterization of hepatocytes and non-parenchymal cells from cirrhotic rats treated with emricasan evidenced a global improvement in cells phenotype. Indeed, and compared to vehicle, hepatocytes exhibited improved synthetic function and expression of key markers, liver sinusoidal endothelial cells had a vasodilator phenotype, hepatic stellate cells became de-activated and macrophages polarized towards a pro-restorative phenotype. Further in vitro experiments confirmed that cirrhotic hepatocytes directly treated with emricasan exhibited significantly improved phenotype, which paracrinally ameliorated liver sinusoidal endothelial cells, macrophages and especially hepatic stellate cells. These paracrine effects were not related to a possible abrogation of apoptotic bodies release by hepatocytes due to emricasan, but to a modification in their secretome machinery.

Importantly, the effects of emricasan improving hepatocytes phenotype were validated in human cirrhotic cells using ExoLiver®, BLB’s proprietary model that mimics the human sinusoid in vitro.

Barcelona Liver Bioservices is a CRO focused on the design and development of pre-clinical research in the field of Hepatology. The company offers cutting-edge research services and consulting to foster the development of new therapeutics for liver diseases, including non-alcoholic steatohepatitis and cirrhosis.

For more information about the company, current partners and available research services please visit www.liver.barcelona

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Inventiva, a clinical stage biopharmaceutical company with expertise in fibrosis, oncology and orphan diseases.

Under the terms of the agreement, which combines the scientific and technical expertise of both companies, BLB will perform cutting-edge research to understand the mechanisms underlying the beneficial effects of Inventiva’s lead compound lanifibranor on liver cirrhosis and portal hypertension. The research plan incorporates different BLB’s models of liver disease, including the unique ExoLiver® platform, to obtain consistent pre-clinical data.

For more information about the services and research developed by BLB please visit www.liver.barcelona

The study describes the benefits of using the ExoLiver® platform to simulate the human liver sinusoid on a chip.
View full article